Literature DB >> 33665158

Comprehensive Analysis of CDCAs Methylation and Immune Infiltrates in Hepatocellular Carcinoma.

Yongkang Wang1, Yinfeng Yang1,2, Honglei Gao1, Ting Ouyang1, Luyao Zhang1, Jili Hu1, Sheng Hu1, Hongxing Kan1,2.   

Abstract

BACKGROUND: As essential components of cycle growth, the cell division cycle-associated family genes (CDCAs) have crucial roles in tumor development and progression, especially in hepatocellular carcinoma (HCC). However, due to the tumor heterogeneity of HCC, little is known about the methylation variability of CDCAs in mediating phenotypic changes (e.g., immune infiltrates) in HCC. Presently, we aim to comprehensively explore the expression and prognosis of CDCAs methylation with regard to immune infiltrates of HCC.
METHODS: We first identified the correlating differentially expressed genes (co-DEGs) among 19 different types of cancer cohorts (a total of 7,783 patients) and then constructed the weighted gene co-expressed and co-methylated networks. Applying the clustering analysis, significant modules of DEGs including CDCAs were selected and their functional bioinformatics analyses were performed. Besides, using DiseaseMeth and TIMER, the correlation between the methylation levels of CDCAs and tumor immune infiltrates was also analyzed. In final, to assess the influence of CDCAs methylation on clinical prognosis, Kaplan-Meier and Cox regression analysis were carried out. RESULT: A total of 473 co-DEGs are successfully identified, while seven genes of CDCAs (CDCA1-3 and CDCA5-8) have significant over-expression in HCC. Co-expressed and co-methylated networks reveal the strong positive correlations in mRNA expression and methylation levels of CDCAs. Besides, the biological enrichment analysis of CDCAs demonstrates that they are significantly related to the immune function regulation of infiltrating immune cells in HCC. Also, the methylation analysis of CDCAs depicts the strong association with the tumor immunogenicity, i.e., low-methylation of CDCA1, CDCA2, and CDCA8 dramatically reduced the immune infiltrate levels of T cells and cytotoxic lymphocytes. Additionally, CDCA1-6 and CDCA8 with low-methylation levels significantly deteriorate the overall survival of patients in HCC.
CONCLUSIONS: The co-expressed and co-methylated gene networks of CDCAs show a powerful association with immune function regulation. And the methylation levels of CDCAs suggesting the prognostic value and infiltrating immune differences could be a novel and predictive biomarker for the response of immunotherapy.
Copyright © 2021 Wang, Yang, Gao, Ouyang, Zhang, Hu, Hu and Kan.

Entities:  

Keywords:  CDCA; DNA methylation; hepatocellular carcinoma; immune infiltrates; predictive biomarker

Year:  2021        PMID: 33665158      PMCID: PMC7921702          DOI: 10.3389/fonc.2020.566183

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  61 in total

1.  CDCA4 is an E2F transcription factor family-induced nuclear factor that regulates E2F-dependent transcriptional activation and cell proliferation.

Authors:  Reiko Hayashi; Yuya Goto; Ryuji Ikeda; Kazunari K Yokoyama; Kenichi Yoshida
Journal:  J Biol Chem       Date:  2006-09-19       Impact factor: 5.157

Review 2.  Epigenetic therapy in immune-oncology.

Authors:  Peter A Jones; Hitoshi Ohtani; Ankur Chakravarthy; Daniel D De Carvalho
Journal:  Nat Rev Cancer       Date:  2019-03       Impact factor: 60.716

3.  Aberrant gene expression profiles in hepatocellular carcinoma detected by microdissection.

Authors:  Y M Wei; Y Y Li; Y C Zhang; Y Q Nie
Journal:  Genet Mol Res       Date:  2013-11-18

4.  HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.

Authors:  Hong Jian Xie; Ji Heon Noh; Jeong Kyu Kim; Kwang Hwa Jung; Jung Woo Eun; Hyun Jin Bae; Min Gyu Kim; Young Gyoon Chang; Jung Young Lee; Hanna Park; Suk Woo Nam
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

5.  Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.

Authors:  Angela D Pardee; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 6.  DiseaseMeth version 2.0: a major expansion and update of the human disease methylation database.

Authors:  Yichun Xiong; Yanjun Wei; Yue Gu; Shumei Zhang; Jie Lyu; Bin Zhang; Chuangeng Chen; Jiang Zhu; Yihan Wang; Hongbo Liu; Yan Zhang
Journal:  Nucleic Acids Res       Date:  2016-11-29       Impact factor: 16.971

7.  CBX2 Regulates Proliferation and Apoptosis via the Phosphorylation of YAP in Hepatocellular Carcinoma.

Authors:  Jiakai Mao; Yu Tian; Chengye Wang; Keqiu Jiang; Rui Li; Yifan Yao; Rixin Zhang; Deguang Sun; Rui Liang; Zhenming Gao; Qi Wang; Liming Wang
Journal:  J Cancer       Date:  2019-06-02       Impact factor: 4.207

8.  Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma.

Authors:  Jing Xu; Chengxiang Zhu; Yue Yu; Weibing Wu; Jing Cao; Zhihua Li; Juncheng Dai; Cheng Wang; Yu Tang; Quan Zhu; Jun Wang; Wei Wen; Lei Xue; Fuxi Zhen; Jinyuan Liu; Chenjun Huang; Fei Zhao; Yue Zhou; Zhicheng He; Xianglong Pan; Haixing Wei; Yining Zhu; Yaozhou He; Jun Que; Jinghua Luo; Liang Chen; Wei Wang
Journal:  EBioMedicine       Date:  2019-07-16       Impact factor: 8.143

9.  Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.

Authors:  Marios Giannakis; Xinmeng Jasmine Mu; Sachet A Shukla; Zhi Rong Qian; Ofir Cohen; Reiko Nishihara; Samira Bahl; Yin Cao; Ali Amin-Mansour; Mai Yamauchi; Yasutaka Sukawa; Chip Stewart; Mara Rosenberg; Kosuke Mima; Kentaro Inamura; Katsuhiko Nosho; Jonathan A Nowak; Michael S Lawrence; Edward L Giovannucci; Andrew T Chan; Kimmie Ng; Jeffrey A Meyerhardt; Eliezer M Van Allen; Gad Getz; Stacey B Gabriel; Eric S Lander; Catherine J Wu; Charles S Fuchs; Shuji Ogino; Levi A Garraway
Journal:  Cell Rep       Date:  2016-04-14       Impact factor: 9.423

10.  Whole-genome bisulfite sequencing in systemic sclerosis provides novel targets to understand disease pathogenesis.

Authors:  Tianyuan Lu; Kathleen Oros Klein; Inés Colmegna; Maximilien Lora; Celia M T Greenwood; Marie Hudson
Journal:  BMC Med Genomics       Date:  2019-10-24       Impact factor: 3.063

View more
  6 in total

Review 1.  RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?

Authors:  Kurt Sartorius; Samuel O Antwi; Anil Chuturgoon; Lewis R Roberts; Anna Kramvis
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  Cell Division Cycle-Associated Genes Are Potential Immune Regulators in Nasopharyngeal Carcinoma.

Authors:  Danxian Jiang; Yin Li; Jinxin Cao; Lianghe Sheng; Xinhai Zhu; Meng Xu
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

3.  Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints.

Authors:  Mengying Tang; Mingchu Liao; Xiaohong Ai; Guicheng He
Journal:  Front Med (Lausanne)       Date:  2022-03-07

4.  Bioinformatic analysis and experimental validation identified DNA methylation-Related biomarkers and immune-cell infiltration of atherosclerosis.

Authors:  Congjian Xu; Di Sun; Changmin Wei; Hao Chang
Journal:  Front Genet       Date:  2022-09-08       Impact factor: 4.772

5.  Multidimensional study of cell division cycle-associated proteins with prognostic value in gastric carcinoma.

Authors:  Peixin Lu; Wen Cheng; Kexin Fang; Bin Yu
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

Review 6.  Epigenetic remodelling in human hepatocellular carcinoma.

Authors:  Maria Rita Braghini; Oriana Lo Re; Ilaria Romito; Maite G Fernandez-Barrena; Barbara Barbaro; Silvia Pomella; Rossella Rota; Manlio Vinciguerra; Matias A Avila; Anna Alisi
Journal:  J Exp Clin Cancer Res       Date:  2022-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.